Annovis Bio, Inc. - 8-K Filing

Annovis Bio reports Q3 2026 net loss of $9.5M and announces $21M public offering to fund DUET-AD data readout in March 2027 (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits Exhibit Number Description 99 Press Release Dated November 13, 2026 104 Cover Page Interactive Data File (e)

SEC EDGAR · November 13, 2026, 21:24 UTC

Tickers: $ANVS

Read the full article at SEC EDGAR

More Regulatory news

Andersen Group Inc. - 8-K Filing SEC EDGAR · November 13, 2026, 21:44 UTC
AltEnergy Acquisition Corp - 10-Q Filing SEC EDGAR · November 13, 2026, 21:43 UTC
AtlasClear Holdings, Inc. - 10-Q Filing SEC EDGAR · November 13, 2026, 21:43 UTC
Amerant Bancorp Inc. - 8-K Filing SEC EDGAR · November 13, 2026, 21:42 UTC
iShares Gold Trust Micro - 8-K Filing SEC EDGAR · November 13, 2026, 21:43 UTC
iShares Silver Trust - 8-K Filing SEC EDGAR · November 13, 2026, 21:42 UTC
ISHARES GOLD TRUST - 8-K Filing SEC EDGAR · November 13, 2026, 21:41 UTC
Tradewinds Universal - 8-K Filing SEC EDGAR · November 13, 2026, 21:41 UTC
iShares Bitcoin Trust ETF - 8-K Filing SEC EDGAR · November 13, 2026, 21:41 UTC
iShares S&P GSCI Commodity-Indexed Trust - 8-K Filing SEC EDGAR · November 13, 2026, 21:40 UTC